{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:32:35Z","timestamp":1754152355858,"version":"3.41.2"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitor\u2013induced type 1 diabetes mellitus (ICI-T1DM) is a rare but serious immune-related adverse event associated with programmed cell death-1 inhibitors such as nivolumab. While previous reports have documented its occurrence, the relationship between nivolumab dosing and the onset of ICI-T1DM remains unclear. This study presents a case of ICI-T1DM following a nivolumab dose and includes a literature review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A man in his 50s (weight: 49.4\u2009kg, body mass index: 17.65\u2009kg\/m<jats:sup>2<\/jats:sup>) with advanced esophageal cancer had been receiving nivolumab (240\u2009mg every 14 days) for over 2 years without adverse effects. Because of treatment adjustments, the dose was increased to 480\u2009mg and administered every 28 days. Ninety-six days after the dose increase, he developed acute-onset fatigue, anorexia, and thirst.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Laboratory tests confirmed diabetic ketoacidosis with hyperglycemia (582\u2009mg\/dL), low C-peptide levels, and negative islet-associated antibodies, leading to the diagnosis of nivolumab-induced fulminant type 1 diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with insulin and discharged after stabilization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>This case suggests that higher dose nivolumab may increase the risk of ICI-T1DM, especially in low body-weight individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Given that nivolumab remains effective at lower doses, dose optimization may help mitigate immune-related adverse events while maintaining therapeutic efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000043356","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:02:41Z","timestamp":1753156961000},"page":"e43356","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Development of type 1 diabetes mellitus after nivolumab dose escalation: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-9457","authenticated-orcid":false,"given":"Sayaka","family":"Mabuchi","sequence":"first","affiliation":[{"name":"Department of Human Resources Development for General Practitioner, Shimane Prefectural Central Hospital, Izumo, Japan"},{"name":"Department of Endocrinology, Shimane Prefectural Central Hospital, Izumo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shimane Prefectural Central Hospital, Izumo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shimane Prefectural Central Hospital, Izumo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nabika","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shimane Prefectural Central Hospital, Izumo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250722","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/09546634.2021.1962002","article-title":"A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014-2019.","volume":"33","author":"Puri","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R2-20250722","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice.","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"R3-20250722","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol Int"},{"key":"R4-20250722","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes.","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol"},{"key":"R5-20250722","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors.","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R6-20250722","doi-asserted-by":"crossref","first-page":"JCO1800045","DOI":"10.1200\/JCO.18.00045","article-title":"Time is money: optimizing the scheduling of nivolumab.","volume":"36","author":"Ratain","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20250722","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes.","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"R8-20250722","doi-asserted-by":"crossref","first-page":"e2246400","DOI":"10.1001\/jamanetworkopen.2022.46400","article-title":"Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma.","volume":"5","author":"Akturk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R9-20250722","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14740338.2024.2448202","article-title":"Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database.","volume":"24","author":"Zhou","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20250722","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"R11-20250722","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors.","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R12-20250722","doi-asserted-by":"crossref","first-page":"1229823","DOI":"10.3389\/fimmu.2023.1229823","article-title":"A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.","volume":"14","author":"Marsiglio","year":"2023","journal-title":"Front Immunol"},{"key":"R13-20250722","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3747\/co.26.4130","article-title":"A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.","volume":"26","author":"Sakaguchi","year":"2019","journal-title":"Curr Oncol"},{"key":"R14-20250722","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"key":"R15-20250722","doi-asserted-by":"crossref","first-page":"e30398","DOI":"10.1097\/MD.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: a case report and review of 8 cases.","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250722","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-024-01263-6","article-title":"Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.","volume":"16","author":"Wei","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"R17-20250722","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/bcp.14369","article-title":"Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.","volume":"86","author":"Peer","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:02:44Z","timestamp":1753156964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":17,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043356","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}